赛托瑞医疗 CYTX 深 沪
已收盘 08-30 16:00:00 美东时间
0.2077
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.2077
- 总市值 376.46万
- 52周最高 562.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 153.00
- 委 比 0.00%
- 总股本 1812.50万
- 历史最高 554625.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 153.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP-Applied Materials, Procter & Gamble, RLI
U.S. RESEARCH ROUNDUP-Applied Materials, Procter & Gamble, RLI Jan 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Procter & Gamble and RLI, on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Be
01-23 15:13
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
Houston-based Plus Therapeutics, Inc. announces it will provide a business update on January 22, 2026, followed by a conference call and webcast at 9:00 AM ET. To join, dial 1-888-349-0106 or visit the provided webcast link. A replay will be available on the company’s website. Plus Therapeutics specializes in developing precision diagnostics and radiopharmaceuticals for CNS cancers.
01-21 21:15
BRIEF-Plus Therapeutics Secures National Coverage Agreement With Humana For Cnside® Cerebrospinal Fluid Assay For Metastatic Cns Cancer
Humana Inc HUM.N: PLUS THERAPEUTICS SECURES NATIONAL COVERAGE AGREEMENT WITH HUMANA FOR CNSIDE® CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER Source text: ID:nGNX4wwSmR Further company coverage:...
2025-11-20 21:14
CytomX Therapeutics to Present at Upcoming September Investor Conferences
<p align="justify">CytomX Therapeutics announced that its management will participate in three investor conferences in September 2025: the Cantor Global Healthcare Conference, H.C. Wainwright 27th Annual Global Investment Conference, and Morgan Stanley 23rd Annual Global Healthcare Conference, all held in New York City. Additionally, live webcasts of their presentations will be available on CytomX’s website, www.cytomx.com. The company focuses on...
2025-08-28 12:00
BRIEF-Plus Therapeutics Regains Compliance With Applicable Nasdaq Listing Criteria
Aug 26 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS REGAINS COMPLIANCE WITH APPLICABLE NASDAQ LISTING CRITERIA Source text: ID:nGNX4gMfhX Further company coverage: PSTV.O ((Reuters.Brie...
2025-08-26 19:31
BRIEF-Plus Therapeutics Presents Positive Respect-LM Trial Results Of Reyobiq In Leptomeningeal Metastases
Aug 18 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS PRESENTS POSITIVE RESPECT-LM CLINICAL TRIAL RESULTS OF REYOBIQ™ IN LEPTOMENINGEAL METASTASES PLUS THERAPEUTICS INC - NO DOSE LIMITING...
2025-08-18 22:15
BRIEF-Plus Therapeutics Q2 Net Income USD 5.151 Million
Aug 14 (Reuters) - Plus Therapeutics Q2 operating income USD -1.538 million. Q2 operating expenses USD 2.928 million
2025-08-15 04:15
BRIEF-Plus Therapeutics Announces $1.6 Million Advance Payment From CPRIT
July 23 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES $1.6 MILLION ADVANCE PAYMENT FROM CPRIT Source text: ID:nGNX2qgtsc Further company coverage: PSTV.O ((Reuters.Briefs@thoms...
2025-07-23 19:43
BRIEF-Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
July 8 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES INITIAL PATIENTS SUCCESSFULLY TREATED IN RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQ™ IN LEPTOMENINGEAL METASTASES PLUS ...
2025-07-08 19:39
BUZZ-U.S. STOCKS ON THE MOVE-Coinbase, Rubrik, AeroVironment
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The benchmark S&P 500 hovered clos...
2025-06-26 00:22
